OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

Outlook Therapeutics shares surged 35% after the FDA accepted its resubmitted Lytenava BLA for wet AMD for review, a key regulatory milestone. The agency set a PDUFA decision date of July 29, 2026, keeping the drug approval timeline alive. The move is clearly positive for the stock, though it remains a binary, event-driven biotech catalyst rather than a broad market driver.

Analysis

Outlook Therapeutics shares surged 35% after the FDA accepted its resubmitted Lytenava BLA for wet AMD for review, a key regulatory milestone. The agency set a PDUFA decision date of July 29, 2026, keeping the drug approval timeline alive. The move is clearly positive for the stock, though it remains a binary, event-driven biotech catalyst rather than a broad market driver.